Gene Therapy Clinical Trials
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Temozolomide
- procedure: Stereotactic Radiosurgery (SRS)
Eligibility
Inclusion Criteria:
- Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must
be made by surgical biopsy or excision
- The tumor must be supratentorial in location
- The planning target volume (tumor plus margin) must measure ≤ 150 cm^3 in volume
- Age ≥ 18 years
- Life expectancy of at least 12 weeks
- Patient must have adequate organ function to tolerate temozolomide (details in the
protocol)
Exclusion Criteria:
- Patients who have previously been treated with brain irradiation to the region that
would result in overlap of the radiation fields
- Tumor foci detected below the tentorium
- Multifocal disease or leptomeningeal spread
- Prior allergic reaction to the study drugs involved in this protocol
- Patients with pacemaker will be allowed to undergo CT instead of MRI
- Pediatric patients (age < 18), pregnant women, and nursing patients will be excluded
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061
Not Recruiting